Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 4

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis

Authors Noll Campbell, Amir Ayub, Malaz A Boustani, Chris Fox, Martin Farlow, et al

Published 5 December 2008 Volume 2008:3(4) Pages 719—728


Review by Single-blind

Peer reviewer comments 4

Noll Campbell1, Amir Ayub2, Malaz A Boustani2, Chris Fox3, Martin Farlow4, Ian Maidment3, Robert Howard5

1Wishard Health Services, Indianapolis, Indiana; 2Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, Indiana; 3University of Kent, Kent, United Kingdom; 4Indiana University School of Medicine, Indianapolis, Indiana; 5King’s College, London, United Kingdom

Objective: To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease (AD).

Data sources: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to English Language, full text, published articles and human studies.

Data extraction: We included randomized, double-blind, placebo-controlled trials evaluating the efficacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, we critically appraised all studies and included only those with an attrition rate of less than 40%, concealed measurement of the outcomes, and intention to treat analysis of the collected data. All data were imputed into pre-defined evidence based tables and were pooled using the Review Manager 4.2.1 software for data synthesis.

Results: We found 12 studies that met our inclusion criteria but only nine of them provided sufficient data for the meta-analysis. Among patients with mild to severe AD and in comparison to placebo, ChEIs as a class had a beneficial effects on reducing BPSD with a standard mean difference (SMD) of −0.10 (95% confidence interval [CI]; −0.18, −0.01) and a weighted mean difference (WMD) of −1.38 neuropsychiatry inventory point (95% CI; −2.30, −0.46). In studies with mild AD patients, the WMD was −1.92 (95% CI; −3.18, −0.66); and in studies with severe AD patients, the WMD was −0.06 (95% CI; −2.12, +0.57).

Conclusion: Cholinesterase inhibitors lead to a statistical significant reduction in BPSD among patients with AD, yet the clinical relevance of this effect remains unclear.

Keywords: Alzheimer’s disease, dementia, cholinesterase inhibitors, behavioral and psychological symptoms

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other articles by this author:

Selecting a change and evaluating its impact on the performance of a complex adaptive health care delivery system

Malaz A Boustani, Stephanie Munger, Rajesh Gulati, et al

Clinical Interventions in Aging 2010, 5:141-148

Published Date: 5 May 2010

The cognitive impact of anticholinergics: A clinical review

Noll Campbell, Malaz Boustani, Tony Limbil, Carol Ott, et al.

Clinical Interventions in Aging 2009, 4:225-233

Published Date: 13 May 2009

The challenge of supporting care for dementia in primary care

Malaz Boustani, Cathy Schubert, Youcef Sennour

Clinical Interventions in Aging 2007, 2:631-636

Published Date: 15 January 2008

Readers of this article also read:

Differential stress reaction of human colon cells to oleic-acid-stabilized and unstabilized ultrasmall iron oxide nanoparticles

Schütz CA, Staedler D, Crosbie-Staunton K, Movia D, Chapuis Bernasconi C, Kenzaoui BH, Prina-Mello A, Juillerat-Jeanneret L

International Journal of Nanomedicine 2014, 9:3481-3498

Published Date: 23 July 2014

Is continuous insulin treatment safe in aneurysmal subarachnoid hemorrhage?

Florian Schlenk, Asita S Sarrafzadeh

Vascular Health and Risk Management 2008, 4:885-891

Published Date: 8 August 2008

Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer’s disease

Tiffany W Chow, Bruce G Pollock, Norton W Milgram

Neuropsychiatric Disease and Treatment 2007, 3:627-636

Published Date: 15 November 2007

Continuous levodopa for advanced Parkinson’s disease

Christofer Lundqvist

Neuropsychiatric Disease and Treatment 2007, 3:335-348

Published Date: 15 July 2007

Conceptualization of depression in Parkinson’s disease

Jeffrey CL Looi, May Matias, Michelle J Ruzich

Neuropsychiatric Disease and Treatment 2005, 1:135-143

Published Date: 15 July 2005

Ongoing clinical trials of the pleiotropic effects of statins

Jean Davignon, Lawrence A Leiter

Vascular Health and Risk Management 2005, 1:29-40

Published Date: 15 April 2005